Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptors

Drug Development Research

Volumn 39, Issue 3-4, 1996, Pages 289-300

  Jacobson, Kenneth A ^a   Suzuki, Fumio ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Adenosine; Agonists; Antagonists; ATP; Structure activity relationships; Xanthines

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; PURINE RECEPTOR; RECEPTOR SUBTYPE; SURAMIN; THEOPHYLLINE;

CONFERENCE PAPER; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; GLIOMA CELL; HUMAN; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 0030441568     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199611/12)39:3/4<289::AID-DDR8>3.0.CO;2-N     Document Type: Conference Paper

References (70)

1. 3 receptors in rat-brain. Mol Pharmacol 48:1038-1045.
2. 2+ -ionophore-induced secretion in a rat mast cell line. J Pharmacol Exp Ther 276:837-845.
3. 2d adenosine receptor antagonists. Curr Med Chem 2:707-722.
4. 3 adenosine receptors. J Med Chem 39:802-806.
5. 2A adenosine antagonists. J Med Chem 39:1164-1171.
6. 1MF-2 cells. J Pharmacol Exp Ther 275:1167-1176.
7. 3 ligands controlling cytokines. Drug Dev Res 37:173.
8. 2y-pnrinoceptors. Br J Pharmacol 113:614-620.
9. 2y pnrinoceptors. Brit J Pharmacol 116:2611-2616.
10. 2Y purinoceptor agonists that are derivatives of adenosine 5′-monophosphate. Br J Pharmacol 118:1959-1964.
11. 2 receptor. J Med Chem 31:1282-1285.
12. Burnstock C (1996) A unifying purinergic hypothesis for the initiation of pain. Lancet 347:1604-1605.
13. 2X-purinoceptor. Br J Pharmacol 90:383-391.
14. 2Y subtypes. Drug Dev Res 31:206-219.
15. Charlton S, Brown CA, Boarder MR (1996): Suramin and PPADS antagonists at transfected P2Y1, P2Y2, P2Y3, and P2Y4 receptors. Drug Dev Res 37:113.
16. Connolly GP (1995) Differentiation by pyridoxal 5-phosphate, PPADS and isoPPADS between responses mediated by UTP and those evoked by α,β-methylenc-ATP on rat sympathetic-ganglia. Br J Pharmacol 114:727-731.
17. 2d adenosine receptor agonists. J Med Chem 38:1462-1472.
18. Cusack NJ, Hourani SMO (1990): Structure activity relationships for adenine nucleotide receptors on mast cells, human platelets, and smooth muscle. In Jacobson KA, Daly JW, Manganiello V (eds): Purines in Cellular Signalling: Targets for New Drugs. New York: Springer, pp. 254-259.
19. 1 receptor mediated responses in rat hippocampus. J Neurosci (in press).
20. Filtz TM, Harden TK, Nicholas RA (1997): Structure, pharmacological selectivity and second messenger properties of G protein coupled P2 purinergic receptors. In Jacobson KA, Jarvis MF (eels): Purinergic Approaches in Experimental Therapeutics. New York: Wiley (in press).
21. 2Y-purinoceptor agonists: Structure-activity-relationships for 2-thioether derivatives of adenosine 5′-triphosphate. J Med Chem 36:3937-3946.
22. Francis JE, Cash WD, Psychoyos S, Ghai G, Wenk P, Friedmann RC, Atkins C, Warren V, Furness P, Hyun JL, et al. (1988): Structure-activity profile of a series ot novel triazoloquinazolinc adenosine antagonists. J Med Chem 31:1014-1020.
23. Freissmuth M, Boehm S, Beindl W, Nickel P, IJzerman AR Hohenegger M, Nanoff TC (1996): Suramin analogues as subtype selective G protein inhibitors. Mol Pharmacol 49:602-611.
24. 3-selective adenosine agonists. J Med Chem 37:636-646.
25. 2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: Characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol 41:352-359.
26. Humphries RG, Leff R Robertson MJ (1996): P2T-purinoceptor antagonists: A novel class of anti-thrombotic agents. Dnig Dev Res 37:175.
27. 2 selective adenosine receptor agonist with preferential hypotensive activity. J Pharmacol Exp Ther 251:47-55.
28. Jacobson KA, van Galen PJM, Williams M (1992a): Perspective. Adenosine receptors: Pharmacology, structure-activity relationships and therapeutic potential. J Med Chem 35:407-422.
29. 6-p-sulfophenylalkyl-and derivatives of adenosine: Water soluble and peripherally selective adenosine agonists. J Med Chem 35:4143-4149.
30. 2-selective adenosine antagonists. J Med Chem 36:1333-1342.
31. 3 adenosine receptors: Design of selective ligands and therapeutic prospects. Drugs Future 20:689-699.
32. Jacobson M, Chakravarty PK, Johnson RG, Norton R (1996): Novel selective non-xanthine A3adenosine receptor antagonists. Drug Dev Res 37:131.
33. Ji XD, Melman N, Jacobson KA (1996): Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem 39:781-788.
34. 3 adenosine receptor antagonists. J Med Chem 39:4667-4675.
35. 3 adenosine receptor antagonists. J Med Chem 39:2293-2301.
36. 2X purinoceptors be classified pharmacologically. Trends Pharmacol Sci 16:168-174.
37. 3 adenosine receptors. J Med Chem 37:3373-3382.
38. 3 adenosine receptors. J Med Chem 37:3614-3621.
39. 3 adenosine receptors: Structure-activity-relationships of 1,3-dialkylxanthine 7-riboside derivatives. J Med Chem 37:4020-4030.
40. 3 receptor subtype. J Med Chem 39:4142-4148.
41. 3H]CCPA): A high affinity agonist radioligand for AI adenosine receptors. Naunyn Schmiedeberg Arch Pharmacol 340:679-683.
42. Knutsen LJS, Lan J, Petersen HJ, Thomsen G, Weis JU, Shalmi M, Judge ME, Hansen J, Sheardown MJ (1997): Novel nenroprotective adenosine agonists with diminished hypotensive effects. J Med Chem (in press).
43. 3 receptor agonists. Biochem Biophys Res Commun 219:904-910. Correction in Biochem Biophys Res Commun (1996) 221:849.
44. Lazarowski ER, Watt WC, Stutts MJ, Brown HA, Boucher RC, Harden TK (1996): Enzymatic-synthesis of UTP-γ-S, a potent hydrolysis resistant agonist of P2n-purinoceptors. Br J Pharmacol 117:203-209.
45. Michel AD, Miller KJ, Buell G, Lundström K, Humphrey PPA (1996): Direct labeling of P2X purinoceptor subtypes. Drug Dev Res 37:113.
46. Müller CE, Hipp J, Knoblauch B, Schobert U, Sauer R, Geis U (1996): DMPX (3,7-dimethyl-1-propargylxanthine) derivatives: Structure activity relationships of potent selective A2a-adenosine receptor antagonists. Drug Dev Res 37:112.
47. 3 adenosine receptor. Mol Pharmacol 45:978-982.
48. 2a adenosine receptor. Mol Pharmacol 48:970-974.
49. 2a selective adenosine receptor antagonist. Br J Pharmacol 115:1096-1102.
50. 1 receptors. J Med Chem 39:1463-1471.
51. 3 adenosine receptor. Proc Natl Acad Sci USA 90:10365-10369.
52. Sarges R, Howard HR, Browne RG, Lebel LA, Seymour PA, Koe BK (1990): 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J Med Chem 33:2240-2254.
53. 1-antagonists for treatment of cognitive deficits. Nucleosides Nucleotides 10:1067-1076.
54. Shimada J, Suzuki F, Nonaka H, Ishii A, Ichikawa S (1992): (E)-1,3-Dialkyl-7-methyl-8-(3,4,5-Trimethoxystyryl)xanthines: Potent and selective adenosine-A2 antagonists. J Med Chem 35:2342-2345.
55. 3 adenosine receptor agonists. Bioorg Med Chem 3:1331-1343.
56. Siddiqi SM, Ji XD, Melman N, Olah ME, Jain R, Evans P, Glashofer M, Padgett WL, Cohen LA, Daly JW, Stiles GL, Jacobson KA(1996): A survey of nonxanthine derivatives as adenosine receptor ligands. Nucleosides Nucleotides 15:693-717.
57. Spedding M, King BF, Dacquet C, Vanhoutte PM, Burnstock G (1996): Specific modulation of P2 receptors by 2,2′-pyridylisatogen (PIT). Drug Dev Res 37:174.
58. 1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure. J Med Chem 35:3066-3075.
59. 1-adenosine receptor. J Med Chem 34:2877-2882.
60. 1 receptor ligands: A test-case for distributed multipole analysis in medicinal chemistry. J Comp Aided Mol Design 9:44-54.
61. van Galen PJM, Nissen P, van Wijngaarden I, IJzennan AR Soudijn W (1991): 1H-imidazo[4,5-c]quinolin-4-amines: Novel non-xanthine adenosine antagonists. J Med Chem 34:1202-1206.
62. 2 purinoceptors. Eur J Pharmacol 268:1-7.
63. van Rhee AM, Siddiqi SM, Melman N, Shi D, Padgett WL, Duly JW, Jacobson KA (1996a): Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists. J Med Chem 39:398-406.
64. 3 receptors. J Med Chem 39:2980-2989.
65. Vittori S, Camaioni E, Di Francesco E, Volpini R, Klotz KN, Lohse MJ, Cristalli G (1996a): Adenosine receptor antagonists: New purine derivatives. Drag Dev Res 37:113.
66. 2A adenosine receptors. J Med Chem 39:4211-4217.
67. 1 receptor agonist. Drug Dev Res 34:276-288.
68. Windscheif U, Pfaff O, Ziganshin AU, Hoyle CHV, Bäumert HG, Mutschler E, Burnstock C, Lambrecht G (1995): Inhibitory action of PPADS on relaxant responses to adenine-nucleotides or electrical-field stimulation in guinea-pig taenia-coli and rat duodenum. Br J Pharmacol 115:1509-1517.
69. 3 adenosine receptor. Proc Natl Acad Sci USA 89:7432-7436.
70. Ziyal R, Ralevic V, Ziganshin AU, Nickel P, Adanuy U, Mutschler E, Lambrecht C, Burnstock G (1996): NF023, a selective P2X-purinoceptor antagonist in rat hamster and rabbit isolated blood vessels. Drug Dev Res 37:113.